Evidence map›Paper›PMID 38805111›Full record

ReviewCurrent diabetes reports2024

Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk.

Corral Pablo, Arrupe Matías, Augusto Lavalle Cobo, Gimenez Sergio, Renna Nicolás Federico

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Lipoprotein(a) as a Risk Factor for Recurrent Ischemic Stroke in Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Corral PabloPharmacology and Research Department, FASTA University, Mar del Plata, Argentina. drpablocorral@gmail.com.
Arrupe MatíasCardiometabolic Unit Coordinator - Hospital Español, Mendoza, Argentina.
Augusto Lavalle CoboHead of Cardiology Department, Sanatorio Otamendi, CABA, Argentina.
Gimenez SergioCardiologist O.S.E.P, Mendoza, Argentina.
Renna Nicolás FedericoChief of Coronary Care Unit - Hospital Español de Mendoza- School of Medicine-UNCuyo, Mendoza, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe objective of this manuscript is to review and describe the relationship between Lp(a) and diabetes, exploring both their association and synergy as cardiovascular risk factors, while also describing the current evidence regarding the potential connection between low levels of Lp(a) and the presence of diabetes. RECENT

findingsEpidemiological studies suggest a potential relationship between low to very low levels of Lp(a) and diabetes. Lipoprotein(a), or Lp(a), is an intriguing lipoprotein of genetic origin, yet its biological function remains unknown. Elevated levels of Lp(a) are associated with an increased risk of cardiovascular atherosclerosis, and coexisting diabetes status confers an even higher risk. On the other hand, epidemiological and genetic studies have paradoxically suggested a potential relationship between low to very low levels of Lp(a) and diabetes. While new pharmacological strategies are being developed to reduce Lp(a) levels, the dual aspects of this lipoprotein's behavior need to be elucidated in the near future.

Indexed as

Cardiovascular DiseasesHeart Disease Risk FactorsLipoprotein(a)Diabetes MellitusHumansRisk FactorsLipoprotein(a)Cardiovascular riskDiabetesLipoprotein aLow lp(a)Lp(a)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.